Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01233882 · ClinicalTrials.gov registry record · Phase 1
Bosutinib In Subjects With Renal Impairment
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT01233882 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 34 participants.
The verdict
NCT01233882, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This is a two-staged study of a single dose of 200 mg of bosutinib given to subjects with renal impairment and matching healthy volunteers. In Stage 1, only subjects with severe renal impairment and subjects with normal renal function will be enrolled. Subjects with mild and moderate renal impairment will be enrolled in Stage 2 if the results from Stage 1 suggest a substantial difference in PK profiles between subjects with severe renal impairment and subjects with normal renal function.
Interventions
- DRUG Bosutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2010-12 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01233882
The ClinicalTrials.gov registry entry for NCT01233882 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bosutinib is the first listed.
NCT01233882 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01233882 about?
NCT01233882 is a clinical study titled "Bosutinib In Subjects With Renal Impairment". This is a two-staged study of a single dose of 200 mg of bosutinib given to subjects with renal impairment and matching healthy volunteers. In Stage 1, only subjects with severe renal impairment and subjects with normal renal function will be enrolled. Subjects with mild and moderate renal impairmen...
What is the current status of trial NCT01233882?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2010-12. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01233882?
The interventions under investigation include: Bosutinib (DRUG).
Who is sponsoring clinical trial NCT01233882?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.